Stockreport

Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Immunome, Inc.  (IMNM) 
PDF – Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq [Read more]